NASDAQ · Financial Statements
Damora Therapeutics, Inc. (DMRA) Financial Statements
$21.08
NASDAQ: DMRA
Market Cap $1.30B
Overview Financials Dividend Damora Therapeutics, Inc. most recently reported annual revenue of $0, net profit of $-210.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-52.0M $-61.0M $-36.0M $-17.0M $-211.0M Net Profit $-52.0M $-62.0M $-38.0M $-21.0M $-210.0M EPS $-51.22 $-60.63 $-36.08 $-18.53 $-152.99 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $122.0M $73.0M $38.0M $17.0M $261.0M Total Liabilities $5.0M $11.0M $6.0M $3.0M $20.0M Cash $63.0M $33.0M $21.0M $14.0M $258.0M Borrowings $1.0M $1.0M $0 $1.0M $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-52.0M $-43.0M $-37.0M $-19.0M $-7.0M Investing Cash Flow $-48.0M $12.0M $22.0M $12.0M $-17.0M Financing Cash Flow $0 $0 $0 $0 $0 Net Cash Flow $-101.0M $-30.0M $-11.0M $-7.0M $243.0M Free Cash Flow $-53.0M $-43.0M $-37.0M $-19.0M $-7.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA -2.93 FCF Yield -3.17% Quick Ratio 19.73 Interest Coverage 0.00 Return 1Y 651.91% Return 3Y -51.43% Return 5Y -74.06%
Screens featuring this stock